52.17

0.56% 0.29

Moonlake Immunotherapeutics (MLTX)

Overview News Price History Option Chain Financials Why MLTX Down? Discussions Forecast

Moonlake Immunotherapeutics stock is traded at $52.17, with a volume of 190.98K. It is up +0.56% in the last 24 hours and up +4.72% over the past month. MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Previous Close:

$51.88

Open:

$51.71

24h Volume:

190.98K

Relative Volume:

0.68

Market Cap:

$3.29B

Revenue:

Net Income/Loss:

$-80.77M

P/E Ratio:

-44.62

EPS:

-1.1692

Net Cash Flow:

$-80.80M

1W Performance:

+1.62%

1M Performance:

+4.72%

6M Performance:

+32.11%

1Y Performance:

-9.32%

1-Day Range:

$50.21

$54.10

1-Week Range:

$50.21

$58.26

52-Week Range:

$37.55

$64.98

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name

Moonlake Immunotherapeutics

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

41 41 510 8022

Address

DORFSTRASSE 29, ZUG

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

MLTX's Discussions on Twitter

Compare MLTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MLTX Moonlake Immunotherapeutics	52.17	3.29B	0	-80.77M	-80.80M	-1.27
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-24	Resumed	Wedbush	Outperform
Aug-26-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-02-24	Initiated	Goldman	Neutral
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-08-23	Initiated	Citigroup	Buy
Nov-02-23	Initiated	Stifel	Buy
Sep-14-23	Downgrade	Bryan Garnier	Buy → Neutral
Aug-31-23	Initiated	Needham	Buy
Jun-15-23	Initiated	Barclays	Equal Weight
May-01-23	Initiated	Guggenheim	Buy
Mar-22-23	Initiated	Wedbush	Outperform
Mar-09-23	Initiated	BTIG Research	Buy
Feb-14-23	Initiated	Cantor Fitzgerald	Overweight
Feb-02-23	Initiated	Bryan Garnier	Buy
Nov-11-22	Initiated	Jefferies	Buy
Aug-25-22	Initiated	SVB Leerink	Outperform
Jul-21-22	Initiated	H.C. Wainwright	Buy
Jul-07-22	Initiated	Cowen	Outperform

View All

Moonlake Immunotherapeutics Stock (MLTX) Latest News

Dec 20, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 3.2%What's Next? - MarketBeat

Dec 20, 2024

Dec 18, 2024

MoonLake Immunotherapeutics announces board change, incentive plan - Investing.com

Dec 18, 2024

MoonLake Immunotherapeutics Announces Board Changes and Incentives - TipRanks

Dec 18, 2024

MoonLake Immunotherapeutics announces board change, incentive plan By Investing.com - Investing.com UK

Dec 18, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 18, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Dec 18, 2024

Dec 17, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 7.9%Here's What Happened - MarketBeat

Dec 17, 2024

Dec 16, 2024

We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate - Simply Wall St

Dec 16, 2024

Wellington Management Group LLP Cuts Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Dec 16, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Dec 16, 2024

Dec 15, 2024

Trading (MLTX) With Integrated Risk Controls - Stock Traders Daily

Dec 15, 2024

Dec 14, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.6%What's Next? - MarketBeat

Dec 14, 2024

Dec 13, 2024

MoonLake Immunotherapeutics' SWOT analysis: stock outlook amid HS market potential - Investing.com

Dec 13, 2024

Dec 12, 2024

Clear Street sets $108 target on Moonlake Immunotherapeutics stock By Investing.com - Investing.com UK

Dec 12, 2024

Clear Street sets $108 target on Moonlake Immunotherapeutics stock - Investing.com

Dec 12, 2024

Dec 10, 2024

MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - MSN

Dec 10, 2024

Dec 06, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by The Manufacturers Life Insurance Company - Defense World

Dec 06, 2024

Dec 05, 2024

When (MLTX) Moves Investors should Listen - Stock Traders Daily

Dec 05, 2024

Dec 04, 2024

Erste Asset Management GmbH Invests $741,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Dec 04, 2024

Dec 02, 2024

Fmr LLC Purchases 1,306,215 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Dec 02, 2024

Nov 25, 2024

Westfield Capital Management Co. LP Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 25, 2024

Nov 24, 2024

(MLTX) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 24, 2024

Nov 23, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $79.00 Consensus PT from Brokerages - MarketBeat

Nov 23, 2024

Nov 21, 2024

MoonLake Immunotherapeutics: A Somewhat Complicated Story (NASDAQ:MLTX) - Seeking Alpha

Nov 21, 2024

Victory Capital Management Inc. Has $10.98 Million Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 21, 2024

Nov 19, 2024

MoonLake Immunotherapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 19, 2024

Nov 18, 2024

MoonLake Immunotherapeutics management to meet with Oppenheimer - TipRanks

Nov 18, 2024

Nov 14, 2024